iScience sees $20.5M for eye surgery instruments
iScience Interventional, maker of surgical tools for eye operations, has closed a prolonged sixth round of funding at $20.5 million after facing a bit more of a challenge due to the economic climate. The money will be used to commercialize its line of micro-catheters used… Continue Reading
Cancer drug maker BiPar sells to Sanofi-aventis for $500M
BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divided into varying milestone payments.
Based in Brisbane, Calif., BiPar creates therapies, primarily… Continue Reading
BiPar snags $20M for inhibitor-based cancer therapies
Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based company’s cash on hand, a huge vote of confidence for its… Continue Reading
Loomia raises $5M to make recommendations
Loomia, which tells users what web content is popular among their friends, has raised $5 million in a first round of funding.
The San Francisco-based startup launched in June 2005 (our coverage of its early features), but it only released its SeenThis? application in January of… Continue Reading
Novocell: With diabetes study pending, investors pony up another $25M
Novocell, a San Diego embryonic stem-cell company, raised $25 million in a third round of funding. That’s presumably a bit of a letdown for the company, which had previously hoped to pull in as much as $35 million in the round. I wrote earlier about… Continue Reading
Koronis: Mutating HIV into extinction
(UPDATED: See below.)
Seattle’s Koronis Pharmaceuticals, a biotech focused on antiviral drugs that cleverly attempt to to drive viruses into extinction, got some serious validation yesterday when it raised $20 million to fund a mid-stage “proof of principle” trial for its leading AIDS drug.
Koronis, which was founded… Continue Reading
Coapt Systems, maker of aesthetic surgery implants, raises $22.6M more
Coapt Systems, a Palo Alto, Ca. maker of bioabsorbable implants for use in aesthetic surgery, has raised $22.6 million in a fifth funding.
The round, led by Global Life Science Ventures and Easton Capital, included existing investors Alta Partners, Asset Management Company, Canaan Partners, Boston… Continue Reading
BiPar Sciences raises $35M for cancer therapies
BiPar Sciences, Inc., a biopharmaceutical company developing cancer therapies, said it has raised $35 million in a second round of financing.
The round was led by Domain Associates. Existing investors participated, including Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners.
BiPar… Continue Reading